Minerva Neurosciences Inc. (NASDAQ:NERV) shares traded down 2.3% during mid-day trading on Friday . The stock traded as low as $11.98 and last traded at $12.06, with a volume of 141,183 shares traded. The stock had previously closed at $12.35.

Several research analysts recently issued reports on the stock. Jefferies Group assumed coverage on shares of Minerva Neurosciences in a research note on Thursday, May 12th. They issued a “buy” rating and a $10.00 price target for the company. Zacks Investment Research upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Thursday, July 7th. Finally, JMP Securities raised their price objective on shares of Minerva Neurosciences from $10.00 to $17.00 in a research note on Thursday, May 26th.

The firm’s 50 day moving average price is $11.67 and its 200-day moving average price is $8.50. The stock’s market capitalization is $423.23 million.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.12. During the same quarter in the previous year, the business earned ($0.27) EPS. Equities research analysts predict that Minerva Neurosciences Inc. will post ($0.90) earnings per share for the current year.

In related news, Director David Kupfer bought 55,635 shares of the stock in a transaction dated Tuesday, June 21st. The stock was purchased at an average cost of $10.84 per share, with a total value of $603,083.40. Following the completion of the purchase, the director now owns 209,188 shares of the company’s stock, valued at $2,267,597.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Venture Associates L. Index III sold 1,000,000 shares of the business’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $10.00, for a total transaction of $10,000,000.00. The disclosure for this sale can be found here.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.